Semliki forest virus as a vector: pros and cons for its use in biopharmaceuticals production

Núñez, Eutímio Gustavo Fernández; Jorge, Soraia Attie Calil; Astray, Renato Mancini; Rezende, Alexandre Gonçalves de; Costa, Bruno Labate Vale da; Monteiro, Daniella Cristina Ventini; Pereira, Carlos Augusto; Tonso, Aldo

doi:10.1590/s1516-89132013000500018

Cited by 4 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, this change allows the expression of a highly pure and bioactive protein, potentially reducing the production costs, since it is possible to produce a greater amount of hGDNF using a smaller number of electroporations and a lower amount of RNA. Even though the quantity of hGDNF produced at a small scale in this study was sufficient for our objective, it would be very interesting to scale-up hGDNF production using this expression system (Núñez et al, 2013, Lundstrom, 2003, Aranda et al, 2014. The ideal situation would be to adapt this method to a process able to handle large volumes of cells with suitable bioreactors.…”

Section: Future Prospects and Conclusionmentioning

confidence: 99%

Optimization of a GDNF production method based on Semliki Forest virus vector

Torres-Ortega

Smerdou

Ansorena

et al. 2021

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Future Prospects and Conclusionmentioning

confidence: 99%

Optimization of a GDNF production method based on Semliki Forest virus vector

Torres-Ortega

Smerdou

Ansorena

et al. 2021

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…At present, industrial production of biopharmaceuticals in cell cultures relies almost exclusively on the use of eukaryotic plasmids (episomes) as expression vectors. On the other hand, the effective systems were developed for temporary (transient) expression and provide substantially higher yields of the expression products (Núñez et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Development of Autonomously Replicating Viral Rna to Express the Recombinant Human Granulocyte Colony-Stimulating Factor

Kaliyeva¹,

Shustov²

2015

CBUP

View full text Add to dashboard Cite

Recombinant human granulocyte colony-stimulating factor (G-CSF) produced in cultured mammalian cells undergoes proper posttranslational modifications and, thereby, possesses better pharmacological properties in comparison with the homologous protein expressed in bacteria. Biopharmaceuticals derived from cell culture tend to be expensive because of lower yields compared to bacterially expressed competitors and numerous issues with the scalability of production. Particular limitation of scalability pertains to delivery of expression vectors to the cell culture. Natural and efficient way to deliver foreign DNA or RNA to cell is a viral infection. We intended to develop the viral genome capable of G-CSF expression.Objectives: To develop autonomously replicating viral RNA capable of heterologous expression of the G-CSF in cultured mammalian cells.Methods: Genetic engineering, cell culture, and virology.

show abstract